Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG035
MIFTS: 54

Lung Large Cell Carcinoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Large Cell Carcinoma

About this section

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 71
Large Cell Lung Carcinoma 12 17
Large Cell Lung Cancer 54

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4556
NCIt 49 C4450
SNOMED-CT 67 254629004
UMLS 71 C0345958
Sources

Summaries for Lung Large Cell Carcinoma

About this section
MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to pulmonary large cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Everolimus and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Sources

Related Diseases for Lung Large Cell Carcinoma

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 31.7 SYP NCAM1 CHGA
2 large cell neuroendocrine carcinoma 31.4 SYP NTRK3 NKX2-1 NCAM1 CHGA
3 adenosquamous carcinoma 29.6 SYP NKX2-1 CHGA
4 adenocarcinoma 29.5 ROS1 NTRK3 NKX2-1 FGFR1 EPHA5 EPHA3
5 lung squamous cell carcinoma 29.5 TTN ROS1 NME1 MTOR FGFR1 EPHA3
6 neuroendocrine carcinoma 29.1 SYP NKX2-1 NCAM1 CHGA
7 small cell carcinoma 28.9 SYP NKX2-1 NCAM1 CHGA
8 lung cancer 28.9 SYP ROS1 NME1 NKX2-1 NCAM1 MYO18B
9 large cell carcinoma 28.1 SYP STK33 ROS1 NTRK3 NKX2-1 NCAM1
10 lung cancer susceptibility 3 28.1 ROS1 NTRK3 NKX2-1 MTOR MIR409 H2AC18
11 lung mixed small cell and squamous cell carcinoma 11.5
12 kidney benign neoplasm 10.5 ROS1 NTRK3 MTOR
13 malignant giant cell tumor of the tendon sheath 10.4 ROS1 NTRK3
14 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.4 FGFR1 ABL1
15 lymphoblastic leukemia, acute, with lymphomatous features 10.4 FGFR1 ABL1
16 rosette-forming glioneuronal tumor 10.3 SYP FGFR1
17 mucinous lung adenocarcinoma 10.2 ROS1 NKX2-1
18 breast neuroendocrine neoplasm 10.2 SYP CHGA
19 primary hepatic neuroendocrine carcinoma 10.2 SYP CHGA
20 acinar cell cystadenocarcinoma 10.2 SYP CHGA
21 vulvar eccrine porocarcinoma 10.2 SYP CHGA
22 cervical large cell neuroendocrine carcinoma 10.2 SYP CHGA
23 appendix carcinoid tumor 10.2 SYP CHGA
24 auditory system cancer 10.2 SYP CHGA
25 mixed ductal-endocrine carcinoma 10.2 SYP CHGA
26 cauda equina neoplasm 10.2 SYP CHGA
27 duodenal benign neoplasm 10.2 SYP CHGA
28 ampulla of vater neoplasm 10.2 SYP CHGA
29 vaginal tubulovillous adenoma 10.2 SYP CHGA
30 breast papillary carcinoma 10.2 SYP CHGA
31 lung meningioma 10.2 SYP NKX2-1
32 lung combined type small cell carcinoma 10.2 SYP NCAM1
33 middle ear adenoma 10.1 SYP CHGA
34 hypoganglionosis 10.1 SYP NCAM1
35 pineocytoma 10.1 SYP CHGA
36 glomangiosarcoma 10.1 SYP NCAM1
37 appendix adenocarcinoma 10.1 SYP CHGA
38 cerebellopontine angle primitive neuroectodermal tumor 10.1 SYP NCAM1
39 spinal cord oligodendroglioma 10.1 SYP FGFR1
40 lung oat cell carcinoma 10.1 SYP CHGA
41 cervix small cell carcinoma 10.1 SYP CHGA
42 thymus clear cell carcinoma 10.1 TTN NKX2-1
43 ureter transitional cell carcinoma 10.1 NCAM1 CHGA
44 acinar cell carcinoma 10.1 SYP NTRK3 CHGA
45 vaginal adenoma 10.0 SYP CHGA
46 thrombocytosis 10.0
47 pulmonary tuberculosis 10.0
48 perivascular epithelioid cell tumor 10.0 SYP NTRK3 NKX2-1
49 ovarian germ cell teratoma 10.0 SYP NKX2-1
50 carcinoid syndrome 10.0 SYP CHGA

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma
Sources

Symptoms & Phenotypes for Lung Large Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.82 MTOR EPHA3
2 Decreased viability GR00055-A-2 10.82 MTOR EPHA3
3 Decreased viability GR00055-A-3 10.82 EPHA3
4 Decreased viability GR00221-A-1 10.82 ABL1 DDR2 FGFR1 MTOR NME1 ROS1
5 Decreased viability GR00221-A-2 10.82 ABL1 DDR2 FGFR1 NME1 ROS1 STK33
6 Decreased viability GR00221-A-3 10.82 ABL1 EPHA5
7 Decreased viability GR00221-A-4 10.82 DDR2 MTOR STK33 EPHA3 EPHA5 NTRK3
8 Decreased viability GR00249-S 10.82 NME1 ROS1 EPHA3
9 Decreased viability GR00301-A 10.82 EPHA3
10 Decreased viability GR00342-S-1 10.82 ABL1 MTOR ROS1 EPHA3 TTN
11 Decreased viability GR00342-S-2 10.82 ABL1 MTOR
12 Decreased viability GR00342-S-3 10.82 ABL1 TTN
13 Decreased viability GR00386-A-1 10.82 FGFR1
14 Decreased viability GR00402-S-2 10.82 DDR2 NME1
15 Decreased cell migration GR00055-A-1 10.01 ABL1 ALPK3
16 Decreased cell migration GR00055-A-2 10.01 NCAM1
17 Decreased cell migration GR00055-A-3 10.01 MTOR NCAM1
18 Decreased substrate adherent cell growth GR00193-A-1 9.8 ROS1
19 Decreased substrate adherent cell growth GR00193-A-2 9.8 ABL1 ALPK3 EPHA3 MTOR ROS1
20 Decreased substrate adherent cell growth GR00193-A-4 9.8 ABL1
21 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.62 EPHA3 FGFR1 MTOR TTN
22 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.54 DDR2 EPHA3 STK33
23 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.13 FGFR1 MTOR ROS1
24 Increased viability GR00386-A-1 8.32 ABL1

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.1 ABL1 ALPK3 CHGA DDR2 EPHA3 FGFR1
2 cardiovascular system MP:0005385 10.06 ABL1 ALPK3 CHGA DDR2 EPHA3 FGFR1
3 muscle MP:0005369 9.76 ABL1 ALPK3 CHGA DDR2 FGFR1 MTOR
4 nervous system MP:0003631 9.7 ABL1 CHGA DDR2 EPHA5 FGFR1 MTOR
5 no phenotypic analysis MP:0003012 9.17 CHGA DDR2 FGFR1 MTOR NKX2-1 NTRK3
Sources

Drugs & Therapeutics for Lung Large Cell Carcinoma

About this section

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
4
Vinblastine Approved Phase 3 865-21-4 241903 13342
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
leucovorin Approved Phase 3 58-05-9 6006 143
7
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
10
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13
Tirapazamine Investigational Phase 3 27314-97-2
14 Hematinics Phase 3
15 Etoposide phosphate Phase 3
16 Epoetin alfa Phase 3 113427-24-0
17 Mitogens Phase 3
18 Antibodies Phase 3
19 Antibodies, Monoclonal Phase 3
20 Immunoglobulins, Intravenous Phase 3
21 Immunoglobulins Phase 3
22 Endothelial Growth Factors Phase 3
23 Immunoglobulin G Phase 3
24 Vitamin B Complex Phase 3
25 Folic Acid Antagonists Phase 3
26 Folate Phase 3
27 Vitamin B9 Phase 3
28 Angiogenesis Inhibitors Phase 3
29 Anti-Bacterial Agents Phase 3
30 Cyclooxygenase 2 Inhibitors Phase 3
31 Anti-Inflammatory Agents Phase 3
32 Analgesics Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Cyclooxygenase Inhibitors Phase 3
35 Antirheumatic Agents Phase 3
36 Anti-Inflammatory Agents, Non-Steroidal Phase 3
37
Lactitol Approved, Investigational Phase 1, Phase 2 585-88-6, 585-86-4 493591
38
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
41
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
42
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
43
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
44
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
45
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
46
Darbepoetin alfa Approved, Investigational Phase 2 11096-26-7, 209810-58-2
47
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
48
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
49
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
50
Lometrexol Investigational Phase 2 106400-81-1

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
3 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
4 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
5 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
6 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
7 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
8 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
9 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
10 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
11 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
12 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
13 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
14 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
15 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
16 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
17 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
18 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
19 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
20 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
21 Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study. Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
22 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
23 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
24 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
25 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
26 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
27 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
28 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
29 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
30 A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
31 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
32 Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase â…¡a Trial Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
33 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
34 A Phase II Study Of Temozolomide In The Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer Completed NCT00006877 Phase 2 temozolomide
35 Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
36 Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2) Completed NCT00003231 Phase 2 cisplatin;docetaxel
37 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
38 Preoperative Chemoradiotherapy In Non-Small Cell Lung Cancer (NSCLC) Patients With Operable Stage IIIB Disease: A Prospective Phase II Trial Completed NCT00030810 Phase 2 Taxotere/Cisplatin
39 Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00025285 Phase 2 carboplatin;irinotecan hydrochloride;thalidomide
40 Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
41 Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
42 VIDEO ASSISTED WEDGE RESECTION (VAR) AND RADIOTHERAPY FOR HIGH RISK T1 NON-SMALL CELL LUNG CANCER: A PHASE II STUDY Completed NCT00002624 Phase 2
43 Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
44 Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel) in Patients With Performance Status = 2,3 or Other Significant Co-Morbidity (HIV Infection or s/p Organ Transplantation) in Advanced Non-Small Cell Lung Cancer Completed NCT00276588 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
45 Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70 Completed NCT00227708 Phase 2 docetaxel
46 Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene Completed NCT00293280 Phase 2 lomustine
47 A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
48 A Phase II Study Evaluating a Maintenance Strategy of Gleevce® (Imatinib Mesylate) and Bevacizumab in Patients With Advanced, Non-squamous, Non-small Cell Lung Cancer, Following Completion of First-line Chemotherapy With Bevacizumab Completed NCT00425646 Phase 2 imatinib mesylate
49 A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor Completed NCT00411047 Phase 2 gefitinib
50 Phase II Clinical Study of Weekly Topotecan in Combination With Avastinâ„¢ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride

Search NIH Clinical Center for Lung Large Cell Carcinoma

Sources

Genetic Tests for Lung Large Cell Carcinoma

About this section
Sources

Anatomical Context for Lung Large Cell Carcinoma

About this section

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

40
Lung, Lymph Node, Brain, Endothelial, Thyroid, Bone, Breast
Sources

Publications for Lung Large Cell Carcinoma

About this section

Articles related to Lung Large Cell Carcinoma:

(show top 50) (show all 221)
# Title Authors PMID Year
1
Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A. 61
32194720 2020
2
Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma. 61
31327819 2019
3
Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. 61
31531741 2019
4
Unraveling the large cell lung carcinoma-specific miRNA profile and the downstream regulation network. 61
31555828 2019
5
Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. 61
31360195 2019
6
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells. 61
31147570 2019
7
Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. 61
31179087 2019
8
Connexin43 Suppresses Lung Cancer Stem Cells. 61
30717421 2019
9
Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. 61
31496800 2019
10
Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. 61
31106047 2019
11
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. 61
30166013 2018
12
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
13
Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. 61
29570944 2018
14
Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. 61
29525405 2018
15
Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. 61
29541373 2018
16
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro. 61
29230631 2018
17
Unravelling the Long Non-Coding RNA Profile of Undifferentiated Large Cell Lung Carcinoma. 61
29657301 2018
18
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. 61
28176646 2018
19
Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. 61
28993508 2018
20
Laparoscopic Splenectomy for Splenic Metastasis from Primary Lung Carcinoma. 61
29732229 2018
21
Correlation between STK33 and the pathology and prognosis of lung cancer. 61
29085482 2017
22
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. 61
28789440 2017
23
[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. 61
28468033 2017
24
Comparison of human lung cancer cell radiosensitivity after irradiations with therapeutic protons and carbon ions. 61
27633574 2017
25
[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]. 61
28219201 2017
26
A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity. 61
27894849 2017
27
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. 61
28790845 2017
28
Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach. 61
28105238 2016
29
[Two Cases of Small Intestinal Metastasis of Lung Cancer]. 61
28133150 2016
30
Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR. 61
26621795 2016
31
Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. 61
27301951 2016
32
Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs. 61
27679544 2016
33
Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma. 61
27507195 2016
34
Treatment of lung large cell neuroendocrine carcinoma. 61
26943800 2016
35
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. 61
26942444 2016
36
Four Cu(ii) complexes based on antitumor chelators: synthesis, structure, DNA binding/damage, HSA interaction and enhanced cytotoxicity. 61
27071545 2016
37
[Large-cell lung carcinoma by the 2015 WHO classification: a clinicopathologic analysis of 93 cases]. 61
27033385 2016
38
Brachial metastatic plexopathy as the inaugural manifestation of lung cancer: multimodality imaging. 61
30460024 2016
39
[A clinical review of 3 cases of children with bronchial tumor]. 61
26696483 2015
40
Digging Deep for New Compounds from the Compass Plant, Silphium laciniatum. 61
26287548 2015
41
Large cell lung carcinoma with rhabdoid phenotype: Report of a rare entity presenting with chest wall involvement. 61
26458655 2015
42
Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology. 61
25793929 2015
43
Lung transthoracic ultrasound elastography imaging and guided biopsies of subpleural cancer: a preliminary report. 61
24951615 2015
44
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. 61
26170921 2015
45
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. 61
25937073 2015
46
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. 61
25638031 2015
47
Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. 61
25776027 2015
48
Association of structural modifications with bioactivity in three new copper(II) complexes of Schiff base ligands derived from 5-chlorosalicylaldehyde and amino acids. 61
25771239 2015
49
A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. 61
25452802 2015
50
Bilateral diffuse uveal melanocytic proliferation with good clinical response to plasmapheresis and treatment of the primary tumor. 61
25383840 2015
Sources

Variations for Lung Large Cell Carcinoma

About this section

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 2927)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 18
2 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 18
3 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 18
4 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 18
5 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 18
6 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 18
7 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 18
8 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 18
9 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 18
10 COSM89575026 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 18
11 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 18
12 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 18
13 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 18
14 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 18
15 COSM127070824 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 18
16 COSM127059821 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 18
17 COSM85195038 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 18
18 COSM130300868 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 18
19 COSM140806401 TTN lung,NS,carcinoma,large cell carcinoma c.62102T>A p.L20701Q 2:178589623-178589623 18
20 COSM140594116 TTN lung,NS,carcinoma,large cell carcinoma c.73050T>C p.D24350= 2:178573082-178573082 18
21 COSM140594104 TTN lung,NS,carcinoma,large cell carcinoma c.101435C>A p.T33812N 2:178535180-178535180 18
22 COSM140594111 TTN lung,NS,carcinoma,large cell carcinoma c.73137C>G p.L24379= 2:178572995-178572995 18
23 COSM85297370 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 6:43283157-43283157 18
24 COSM131090496 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 18
25 COSM131094722 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 18
26 COSM131094002 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 18
27 COSM87049256 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 18
28 COSM85721789 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 18
29 COSM94305492 TRRAP lung,NS,carcinoma,large cell carcinoma c.8069C>T p.P2690L 7:98976613-98976613 18
30 COSM97140529 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 9:74782752-74782752 18
31 COSM91855448 TRIB1 lung,NS,carcinoma,large cell carcinoma c.1113C>G p.F371L 8:125436465-125436465 18
32 COSM90140992 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 18
33 COSM90145840 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 18
34 COSM87090089 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 18
35 COSM87898991 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 18
36 COSM87897745 TP53 lung,NS,carcinoma,large cell carcinoma c.524G>A p.R175H 17:7675088-7675088 18
37 COSM87901497 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.461G>T p.G154V 17:7675151-7675151 18
38 COSM87906616 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 17:7674238-7674238 18
39 COSM87935416 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.499C>T p.Q167* 17:7675113-7675113 18
40 COSM87897711 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>A p.R273H 17:7673802-7673802 18
41 COSM87897832 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 18
42 COSM87924356 TP53 lung,NS,carcinoma,large cell carcinoma c.589G>A p.V197M 17:7674942-7674942 18
43 COSM87904420 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.514G>T p.V172F 17:7675098-7675098 18
44 COSM87897883 TP53 lung,NS,carcinoma,large cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 18
45 COSM87898444 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.536A>G p.H179R 17:7675076-7675076 18
46 COSM87900157 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>T p.R273L 17:7673802-7673802 18
47 COSM87991360 TP53 lung,NS,carcinoma,large cell carcinoma c.714T>A p.C238* 17:7674249-7674249 18
48 COSM87901016 TP53 lung,NS,carcinoma,large cell carcinoma c.734G>T p.G245V 17:7674229-7674229 18
49 COSM87898723 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 17:7673803-7673803 18
50 COSM87906107 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.473G>T p.R158L 17:7675139-7675139 18
Sources

Expression for Lung Large Cell Carcinoma

About this section
Search GEO for disease gene expression data for Lung Large Cell Carcinoma.
Sources

Pathways for Lung Large Cell Carcinoma

About this section

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.56 ROS1 NTRK3 MYO18B MTOR FGFR1 EPHA5
2
Akt Signaling 63
Show member pathways
 13.17 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
3
p70S6K Signaling 63
Show member pathways
 12.73 NTRK3 MTOR FGFR1 EPHA5 EPHA3 DDR2
4
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.53 ROS1 NTRK3 MYO18B FGFR1 EPHA5 EPHA3
5
G-protein signaling RAC1 in cellular process 22
Show member pathways
 11.8 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
6
Guidance Cues and Growth Cone Motility 63
11.63 NTRK3 EPHA5 EPHA3 ABL1
7
Neural Stem Cells and Lineage-specific Markers 64
11.53 SYP NCAM1 FGFR1
8
Central carbon metabolism in cancer 36
11.43 NTRK3 MTOR FGFR1
9
Tyrosine Kinases / Adaptors 4
11.27 ROS1 FGFR1 EPHA5 EPHA3 DDR2 ABL1
10
G-protein signaling_Rap2B regulation pathway 22
10.7 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
Sources

GO Terms for Lung Large Cell Carcinoma

About this section

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.56 SYP STK33 SPINK5 ROS1 NME1 EPHA5
2 receptor complex GO:0043235 9.1 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.06 SPINK5 ROS1 NTRK3 FGFR1 EPHA5 EPHA3
2 protein phosphorylation GO:0006468 9.9 TTN STK33 ROS1 NTRK3 MTOR FGFR1
3 axon guidance GO:0007411 9.83 NKX2-1 NCAM1 EPHA5 EPHA3
4 protein autophosphorylation GO:0046777 9.8 STK33 MTOR FGFR1 DDR2 ABL1
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
6 positive regulation of neuron projection development GO:0010976 9.77 NTRK3 NME1 MTOR FGFR1 EPHA3
7 regulation of GTPase activity GO:0043087 9.74 MTOR EPHA5 EPHA3
8 ephrin receptor signaling pathway GO:0048013 9.73 NTRK3 EPHA5 EPHA3
9 regulation of actin cytoskeleton organization GO:0032956 9.73 MTOR EPHA5 EPHA3 ABL1
10 positive regulation of kinase activity GO:0033674 9.73 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
11 hippocampus development GO:0021766 9.69 NME1 NKX2-1 EPHA5
12 regulation of T cell differentiation GO:0045580 9.58 SPINK5 ABL1
13 positive regulation of phospholipase C activity GO:0010863 9.58 NTRK3 FGFR1
14 peptidyl-tyrosine phosphorylation GO:0018108 9.56 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
15 cardiac muscle fiber development GO:0048739 9.55 TTN MYO18B
16 signal transduction in response to DNA damage GO:0042770 9.54 STK33 ABL1
17 cardiac muscle cell development GO:0055013 9.49 MTOR ALPK3
18 regulation of phosphate transport GO:0010966 9.48 ROS1 FGFR1
19 phosphorylation GO:0016310 9.4 TTN STK33 ROS1 NTRK3 NME1 MTOR

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.18 TTN STK33 ROS1 NTRK3 NME1 MTOR
2 nucleotide binding GO:0000166 10.15 TTN STK33 ROS1 NTRK3 NME1 MYO18B
3 ATP binding GO:0005524 10.13 TTN STK33 ROS1 NTRK3 NME1 MYO18B
4 protein kinase activity GO:0004672 9.85 TTN STK33 ROS1 NTRK3 MTOR FGFR1
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.73 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
6 SH2 domain binding GO:0042169 9.63 SYP FGFR1 ABL1
7 GPI-linked ephrin receptor activity GO:0005004 9.61 NTRK3 EPHA5 EPHA3
8 protein tyrosine kinase activity GO:0004713 9.56 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
9 ephrin receptor activity GO:0005003 9.48 EPHA5 EPHA3
10 kinase activity GO:0016301 9.4 TTN STK33 ROS1 NTRK3 NME1 MTOR
Sources

Sources for Lung Large Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....